anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hypersensitivity reactions with chills, fever and urticaria as the most usual manifestations and also asthma, rhinitis, lacrimation, and anaphylactoid reactions have been reported. Patients with documented hypersensitivity to heparin should be given the drug only in clearly life-threatening situations [see Adverse Reactions (6.1)].

Because Heparin Sodium in 5% Dextrose Injection is derived from animal tissue, monitor for signs and symptoms of hypersensitivity when it is used in patients with a history of allergy to pork products.

This product contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
1,253,606. Dextranase. MERCK & CO. Inc. 28 Oct., 1969 [7 Nov., 1968], No. 52777/69. Heading C3H. A method of recovering purified dextranase from a crude solution comprises adding ferric ions to the crude solution to form a precipitate with the dextranase, recovering the precipitate and releasing the dextranase from it by addition of a substantially neutral electrolyte solution and then desalting the released dextranase. Depending upon the salt concentration in the crude solution and the pH thereof, ferric ions can also be used to precipitate impurities, having the dextranase in solution.
A product use and behavior instrument includes a housing defining a central compartment therein. A controller is positioned within the central compartment. The controller includes a first connector. The first connector is configured to operatively and removably couple the product use and behavior instrument to a battery element. A second connector is configured to operatively and removably couple the product use and behavior instrument to a tank element. A sensor circuit is structured to collect at least one use data characteristic of a smoking action. The smoking action is associated with use of at least one of the tank and battery element. Local memory is structured to store the at least one use data characteristic of the smoking action. A communication interface is structured to communicate the stored at least one use data characteristic of the smoking action to a remote computing device.
A process of manufacturing tablets and the like by compressing a conventional compound powder containing a binder is characterized in that the binder is mixed with one or more of the constituents forming the major part of the compound powder and such a small amount of a liquid in which the binder dissolves or swells that, on the one hand, the binder is distributed homogeneously over the surface of the individual particles of the said constituent but, on the other hand, no coherence of the mass occurs and the product obtained is dried, if necessary, and mixed with the other constituent or constituents of the powder to be compressed.  The binder employed is selected according to the nature of the substance to be tabletted.  For substantially non-wettable water-insoluble substances e.g. sulphur and chloramphenical, a non-ionogenic, water-soluble cellulose derivative such as methyl cellulose is used.  For wettable, water-insoluble substance such as procaine penicillin, an ionogenic cellulose derivative may be used.  For water-soluble, water stable substances e.g. saccharose, an ionic cellulose derivative may be used.  For water-soluble substances, which decompose in water, a non-ionic cellulose derivative soluble in a non-aqueous liquid, e.g. an acetone solution of ethyl cellulose, may be used.
OBJECTIVE: Surgery is the mainstay of hepatic cystic echinococcosis (HCE). The conservative surgery of HCE carries a non-negligible risk of recurrence and significant morbidity, dominated by Deep Surgical Site Infections (DSSI). To address these issues, we have improved and standardized this technique, which could reduce complications and achieve better postoperative outcomes.
PATIENTS AND METHODS: We conducted a prospective study from June 2017 to June 2022 involving of patient operated using a standardized open technique for uncomplicated HCE at Habib Bourguiba University Hospital, Sfax, Tunisia. The aim was to obtain results at least similar to radical management in terms of DSSI. Patients with large cystobiliary fistulas or patients with complicated cysts were excluded.
RESULTS: Fifty patients with 106 cysts were operated using the standardized technique comprising of liver mobilization, intraoperative ultrasound, systematic methylene blue injection to detect cystobiliary fistulas and omentoplasty. The median age of the patients was 44(semi-interquartile range: 16) years. The main symptom described by the patient was pain in 43 cases (86%). An abnormal liver test was found in 20 cases (40%). On imaging studies, the cyst had a median size of 7.4(3.0) cm. Cyst of the hepatic dome accounted for 38 cases (35.8%) with most cysts being situated in the right hemi-liver. Visual inspection of the cavity and Methylene blue testing allowed for the discovery of 57 cysts (53.7%) that had cystobiliary fistulas that were sutured. Omentoplasty was performed in 77 cysts (72.6%). Postoperatively, only 2 cases (1.9%) developed a DSSI in the form of an external bile leak with resolved with conservative management. No case of recurrence was found after a median follow-up of 24 months.
CONCLUSION: The standardized conservative surgical technique, in selected patients, shows promise in reducing DSSI rates and overall morbidity, and achieve as equally good result as radical management.
This study consists of evaluating the safety and efficacy of energy sealing lobar PA branches for lobectomy in humans. All patients planned to undergo a lobectomy by VATS at the CHUM - Hôpital Notre-Dame will be approached. In our institution, lobectomies are either done open (thoracotomy) or by minimally invasive approach, known as VATS (video assisted thoracoscopic surgery). This decision is based on the surgeon, tumor size, tumor localization and patient characteristics. Only patients already planned for a VATS lobectomy will be approached. Potential patients will be selected by going over the operation request forms. Patients booked for a VATS lobectomy will be approached either in the preoperative clinic or the day before surgery, when admitted. Aim is to recruit 20 patients.
PURPOSE:To collect a novel immunoactivator by cultivating a bacterium Rhodococcus, and to use it as an antitumor agent or a preventive against infection with microorganisms. CONSTITUTION:A bacterium such as Rhodococcus terrae IFO70012, etc. belonging to the genus Rhodococcus, capable of production novel immunoactivator Rt-1, is cultivated. The cultivation is aerobically carried out in a medium containing a carbon source such as a carbohydrate, an alcohol, etc., a nitrogen source such as potassium nitrate, meat extract, etc., an inorganic salt, a vitamin, etc., and after the cultivation is over, Rt-1 is obtained from the mold. The culture mold is extracted with a solvent such as an ether, chloroform, etc., an extract is injected into chromatography to collect Rt-1 fraction. The prepared immunoactivator Rt-1 has low toxicity and excellent immunoactivating action.
Syringe one contains 40 ml NaCl 9 mg.ml-1 and Syringe two contains Remifentanil 2 mg in 40 ml NaCl 9 mg.ml-1 = 50 µg.ml-1 which will be infused at a rate of 0.9 µg.kg-1.min-1. According to randomization syringe one will be tapered towards the end of surgery and syringe two abruptly stopped.
This invention relates to a novel recombinant chimera of DNA construct having esat-6 region of Mycobacterium tuberculosis and kinesin region of Leishmania donovani cloned together on two sides of self cleaving peptide in a DNA vaccine vector pVAX-1 wherein the Chimeric construct is operatively linked to a transcriptional promoter thus capable of self replication and expression within the mammalian cell and the process of preparation thereof comprising. Analysis of the predicted protein sequence of kinesin motor domain and esat-6 domain using Promiscuous MHC Class-1 Binding Peptide Prediction Servers. Amplification of gene coding for kinesin motor domain and esat-6 domain. Cloning of kinesin esat-6 gene region in pGEM-T® vector for sequence analysis. Generation of Chimeric construct by directional cloning in pVAX-1 vector. In-vitro expression analysis of kenesin motor domain and esat-6 domain from the clones using cell free translation system and immunogenicity studies, Splenocyte proliferative and cytokines studies using the above mentioned constructs.
BACKGROUND: Submucosal pseudoinvasion and squamous metaplasia (SM) are incidental and special morphological findings in colorectal adenomas, and both can mimic invasive carcinoma. The coexistence of these two findings further increases the risk of misdiagnosis, posing a great diagnostic challenge to pathologists. From 1979 to 2022, only 8 cases have been reported, which was extremely rare. In this report, we presented a case of sigmoid colon adenoma accompanied by pseudoinvasion and SM. Additionally, relevant literature was analyzed to summarize the clinical and pathological characteristics.
CASE PRESENTATION: A 51-year-old Chinese male patient presented with fresh blood after defecation. Electronic colonoscopy revealed multiple polyps, which were removed using a snare and subjected to high-frequency electrocoagulation resection. The largest polyp, located in the sigmoid colon, was a thick pedunculated and lobulated polyp with a maximum diameter of 2.8 cm. The surface of the polyp showed slight ruggedness and redness, and it was sent for pathological examination. Grossly, the polyp had a lobulated and slightly rough surface. Microscopically, it showed a tubulovillous adenoma with focal high-grade dysplasia and mucosal muscle hyperplasia. Glandular elements were observed in the submucosal layer, forming a well-defined lobular structure. Some of the glands displayed cystic change, and focal SM could be seen within the adenoma. SM could manifest as discrete solid cell nests of varying sizes or cribriform-morular-like structures. Immunohistochemical staining showed that SM cells were diffusely positive for cytokeratin 5/6 (CK5/6); p40, p63, and cytokeratin 20 (CK20) were negative; while caudal type homeobox 2 (CDX2) was weakly positive. β-catenin showed abnormal nuclear expression, and an extremely low Ki67 proliferation index was observed.
CONCLUSIONS: Coexistence of SM and pseudoinvasion in colorectal adenomas is highly rare. It is more commonly observed in males and tends to occur in the sigmoid colon. It primarily manifests in tubulovillous adenoma and tubular adenoma, with a majority of cases exhibiting a pedicle. Histologically, it is similar to invasive lesions. The cystic dilation of the submucosal glands, hemosiderin deposition, and the presence of a lamina propria around the submucosal glands without adjacent desmoplastic reaction, suggest pseudoinvasion rather than cancer. The bland cytological morphology and Immunohistochemical markers play a crucial role in distinguishing SM from true invasive lesions.
A fistula evaluation system includes an extraction device and an evaluation device. The extraction device includes a transmitting antenna, a receiving antenna, an emitting module, and a receiving module. The emitting module transmits a radio carrier wave to the fistula via the transmitting antenna, and the receiving module receives an echo signal reflected from the radio carrier wave and outputs the echo signal as a transmission signal. The evaluation device includes a differential processing module, a digital filter module, and a conversion recognition module. The differential processing module performs differential processing on the transmission signal for time and then outputs it as the differential signal. The digital filter module filters the differential signal into a frequency band of 0.8~10 Hz and outputs it as the filter signal. The evaluation device differentiates and digitally filters the transmission signal and converts it into a plurality of image files. The image recognition of the image files is performed to output an evaluation result. In this way, the information implicitly included in the echo signal can be used to detect the blood flow condition of the fistula. Moreover, its implementation structure is affordable and easy to operate and no consumables are required. It is adapted to be used as a routine vascular access monitoring method in hospitals. The present invention also provides a fistula evaluation method suitable for measuring and evaluating the access status of a fistula of a subject. The fistula evaluation method includes the following steps of (A) transmitting a radio carrier toward the fistula and receiving an echo signal reflected by the radio carrier; (B) outputting the echo signal as a transmission signal; (C) differentiating and digitally filtering the transmission signal into a filter signal and converting the filter signal into a plurality of image files; and (D) performing image recognition on the image files to output an evaluation result.
The Freespira Breathing System (FBS) developed by Palo Alto Health Sciences, Inc, is a portable home device used for breathing biofeedback in adults with PD. FBS has now received FDA clearance for the treatment of PD adults and is currently commercially available and more than 150 therapist have provided the service nationally. However, FBS has not yet been tested for efficacy in a pediatric populations. Due to its portability, FBS may pose an advantage for use in younger age groups, compared to multiple therapy sessions required for CBT or lower acceptability for long-term medication use for adolescent PD. In this pilot intervention study, the efficacy of the FBS system in youth will be tested.
Method and apparatus for recommending clinical trials for patients. Embodiments include determining a plurality of clinical trials that a first patient is eligible to participate in. Embodiments further include determining a plurality of current attributes of the first patient. Embodiments further include determining a plurality of predicted attributes of the first patient for a future point in time. Embodiments further include generating a fitness measure for each of the plurality of clinical trials, with respect to the first patient, by processing data about each of the plurality of clinical trials, the plurality of current attributes, and the plurality of predicted attributes with a machine learning (ML) model. Embodiments further include ranking the plurality of clinical trials based on the generated fitness measures.
Renal ischaemia-reperfusion injury (RIRI) is a primary cause of acute kidney damage, occurring frequently in situations like renal transplantation, yet the underlying mechanisms were not fully understood. Sentrin-specific protease 1 (SENP1) is an important member of the SENP family, which is widely involved in various diseases. However, the role of SENP1 in RIRI has been unclear. In our study, we discovered that SENP1 was involved in RIRI and reduced renal cell apoptosis and oxidative stress at elevated levels. Further mechanistic studies showed that hypoxia-inducible factor-1α (HIF-1α) was identified as a substrate of SENP1. Furthermore, SENP1 deSUMOylated HIF-1α, which reduced the degradation of HIF-1α, and exerted a renoprotective function. In addition, the protective function was lost after application of the HIF-1α specific inhibitor KC7F2. Briefly, our results fully demonstrated that SENP1 reduced the degradation of HIF-1α and attenuated oxidative stress and apoptosis in RIRI by regulating the deSUMOylation of HIF-1α, suggesting that SENP1 may serve as a potential therapeutic target for the treatment of RIRI.
The study consists of a Screening Period (Day -28 to Day -1), a 24-week treatment period (Part A and Part B), and an expected 12-week Follow-up Period. Patients with Relapsing Multiple Sclerosis will be randomized in 2:1 ratio to obexelimab or placebo. Randomization will be stratified by Gd lesion status at screening (≥ 1 vs 0).

Part A is the 12-week Randomized Placebo-Controlled Period (RCP), during which obexelimab or placebo will be administered as weekly subcutaneous (SC) injections. Following Part A, all patients will enter the Part B, Open-Label Period (OLP), during which all patients will receive obexelimab administered as weekly SC injections. Patients will return for an in-clinic Safety Follow-Up Visit 12 weeks after the completion of Part B (i.e. Week 36). If at this time, B cells have not returned to baseline or above the lower limit of normal (LLN), patients will be asked to return every 12 weeks until B cells return to baseline or above the LLN (at minimum). The maximum expected duration of the study is 40 weeks (Screening Period = 4 weeks, Parts A and B = 24 weeks, Follow-up Period = 12 weeks).
Following antiseptic preparation of block site linear ultrasound probe was placed longitudinally to midline just above the sacrum. After the median sacral crests and erector spinae were identified, a 22G, 50 mm block needle was advanced from the cranial to the caudal direction until it touched the top of the 4th median sacral crest with the in-plane technique. After hydrodissection was achieved with 1 ml of saline, 0.5 ml/kg of 0.25% bupivacaine was administered after negative aspiration.
Treatment Period 1: continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 1. Treatment Period 2: optional continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 2.
PURPOSE:To produce a monoclonal antibody, stably and continuously, by fusing a mouse myeloma cell with a peripheral blood lymphocyte obtained from a man immunized with HBS antigen, and cloning the obtained hybridoma. CONSTITUTION:Hepatitis B vaccine is administered to a man by subcutaneous injection, and the produced peripheral blood lymphocyte is collected and cultured in vitro. In the above process, the peripheral blood lymphocyte is activated with a lymphocyte activating substance such as PWM. The produced peripheral blood lymphocyte is recovered, fused with a mouse myeloma cell (e.g. X63-Ag8-6,5,3) in the presence of a fusion agent to produce a mouse x human hybridoma. For the continuous production of a human anti-HBS monoclonal antibody, the above hybridoma is cloned, and the hybridoma clone is produced in vitro or in the living body of an immunoinsufficient animal such as nude mouse.
The invention discloses a nifedipine slow-release tablet for treating hypertensive emergency and a preparation technology thereof. The nifedipine slow-release tablet is composed of a quick-release pellet, a slow-release pellet and other auxiliary materials which are acceptable in pharmacy. The quick-release pellet sequentially comprises a core pellet, a separating coating layer and a medicine-containing layer. The medicine-containing layer is composed of nifedipine, hydroxy propyl cellulose and copovidone VA64. The slow-release pellet is composed of slow-release coating of the slow-release pellet. According to the nifedipine slow-release tablet for treating the hypertensive emergency, the purposes of quick effect taking, long-term stable medicine release and complete later-period medicine release are achieved, so that the need of curing the hypertensive emergency is met.
Oxybutynin chloride extended-release tablet, USP is an antispasmodic, muscarinic antagonist. Each oxybutynin chloride extended-release tablet, USP contains 5 mg, 10 mg, or 15 mg of oxybutynin chloride USP, formulated as a once-a-day controlled-release tablet for oral administration. Oxybutynin chloride is administered as a racemate of R- and S-enantiomers.

Chemically, oxybutynin chloride is d,l (racemic) 4-diethylamino-2-butynyl phenylcyclohexylglycolate hydrochloride. The empirical formula of oxybutynin chloride is C 22H 31NO 3•HCl. 

Its structural formula is:

Oxybutynin chloride is a white crystalline solid with a molecular weight of 393.9. It is readily soluble in water and acids, but relatively insoluble in alkalis.

Oxybutynin chloride extended-release tablets, USP contains the following inert ingredients: colloidal anhydrous silicon dioxide, hypromellose, lactose monohydrate, magnesium stearate, methacrylic acid copolymer type-c, microcrystalline cellulose, polyethylene glycol, sodium bicarbonate, sodium lauryl sulfate, talc, titanium dioxide, triethyl citrate. Coloring agents are ferric oxide yellow (in all strengths), ferric oxide red (in 5 mg and 10 mg only) and ferric oxide black (in 15 mg only).

System Components and Performance

Oxybutynin chloride extended-release tablets, USP are formulated to deliver oxybutynin chloride at a controlled rate over approximately 24 hours. The dosage form is comprised of a hydrophilic cellulose polymer matrix tablet surrounded by an enteric coating system. The enteric coat is insoluble in the low pH environment of the stomach. As the tablet passes through the stomach and enters the higher pH environment of the small intestine, the enteric coating dissolves and/or erodes to expose the polymer matrix tablet which swells and releases drug at a controlled rate via diffusion and/or erosion.

Oxybutynin chloride extended-release tablets, USP meets USP dissolution test 5.
This study will involve two cohorts of patients, A and B. Patients are invited because they have either (A) locally recurrent or metastatic nasopharyngeal cancer; or (B) stage 4 locally advanced nasopharyngeal cancer (N2 or N3 disease and/or T4) and is known to be associated with a high risk of distant relapse.

This study is carried out to find out the safety and recommended dose of CD137L-DC-EBV-VAX in nasopharyngeal cancer. CD137L-DC-EBV-VAX is a product made from one of our own immune system cells (dendritic cell, DC). Dendritic cells are immune cells that help to stimulate our body's T lymphocytes to fight cancer by presenting specific proteins from the cancer cells. The investigators have developed in the laboratory a highly effective dendritic cell which is primed to activate T cells with the Epstein-Barr virus (EBV) proteins. It is hoped that this will stir an immune response to recognize NPC cells and kill them as part of body's immune surveillance system.
Palifermin 180 μg/kg on Day -3 and placebo on Days -1 and -2 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC. Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.